{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Spicer J"],"funding":["Cancer Research UK","Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["4180"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10368744"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha. The trial incorporated skin prick and basophil activation tests (BAT) to select patients at lowest risk of allergic toxicity. Secondary objectives were exploration of anti-tumour activity, recommended Phase II dose, and pharmacokinetics. Dose escalation ranged from 70 μg-12 mg. The most common toxicity of MOv18 IgE is transient urticaria. A single"],"journal":["Nature communications"],"pubmed_title":["Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial."],"pmcid":["PMC10368744"],"funding_grant_id":["N/A","11060","C604/A25135","RP-2016-07-028","NIHR205044","MR/L023091/1"],"pubmed_authors":["Montes A","Chauhan J","Barton C","Stavraka C","Ilieva KM","Miller R","Gillett C","Basu B","Mellor S","Selkirk C","Funingana IG","Kristeleit R","Figini M","Gould HJ","Doherty G","Till SJ","Pinder S","Nakamura M","Bax HJ","Spicer J","Banerji U","Karagiannis SN","Pellizzari G","Khiabany A","Canevari S","Veal GJ","Josephs DH","Jones P","Nintos G","Carroll S","Corrigan CJ","Kwatra V"],"additional_accession":[]},"is_claimable":false,"name":"Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.","description":"All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha. The trial incorporated skin prick and basophil activation tests (BAT) to select patients at lowest risk of allergic toxicity. Secondary objectives were exploration of anti-tumour activity, recommended Phase II dose, and pharmacokinetics. Dose escalation ranged from 70 μg-12 mg. The most common toxicity of MOv18 IgE is transient urticaria. A single","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-05-29T10:18:47.952Z","creation":"2025-04-07T04:18:05.083Z"},"accession":"S-EPMC10368744","cross_references":{"pubmed":["37491373"],"doi":["10.1038/s41467-023-39679-9"]}}